麝香保心丸联合丹参多酚酸盐对冠心病心绞痛患者心功能及血清CRP与Hcy水平的影响

目的:探讨麝香保心丸联合丹参多酚酸盐治疗冠心病心绞痛的临床疗效。方法:选择2014年5月-2016年5月我院收治的冠心病心绞痛患者94例,根据治疗方法不同分为研究组和对照组,每组47例。对照组患者给予丹参多酚酸盐注射液治疗,研究组患者在对照组基础上给予麝香保心丸口服治疗。观察并比较两组患者治疗前后心功能指标及血清同型半胱氨酸(Hcy)及C反应蛋白(CRP)水平。结果:与治疗前比较,两组患者治疗后Pro-BNP,LVEDD及E/A均降低,而LVEF均升高,差异具有统计学意义(P0.05);与对照组比较,研究组治疗后Pro-BNP,LVEDD及E/A较低,而LVEF较高,差异具有统计学意义(P0.05)。与治疗前比较,两组患者治疗后血清Hcy及CRP水平均升高,差异具有统计学意义(P0.05);与对照组比较,研究组患者治疗后血清Hcy及CRP水平较高,差异具有统计学意义(P0.05)。研究组患者临床总有效率显著高于对照组,差异具有统计学意义(P0.05)。结论:麝香保心丸联合丹参多酚酸盐治疗冠心病心绞痛具有显著的临床疗效,可以改善患者心功能,促进冠状动脉血流畅通,值得临床推广应用。

Effect of Shexiangbaoxin Capsules and Salvia Miltiorrhiza on Heart Function and Serum Levels of CRP and Hcy in Patients with Coronary Heart Disease and Angina Pectoris

ABSTRACT Objective: To investigate the clinical effect of shexiangbaoxin capsules combined with salvia miltiorrhiza polyphenols on the treatment of coronary heart disease and angina pectoris. Methods: 94 cases with angina pectoris and coronary heart disease who were admitted in our hospital from May 2014 to May 2016 were selected and according to the different treatment methods, the patients were divided into the study group and the control group with 47 cases in each group. The patients in the control group were treated with salvia miltiorrhiza, and the patients in the study group were treated with shexiangbaoxin capsules on the basis of the control group. Then the cardiac function indexes and serum levels of homocysteine (Hcy) and C reactive protein (CRP) in the two groups were observed and compared before and after the treatment. Results: Compared with before treatment, the Pro-BNP, LVEDD and E/A in the two groups decreased after the treatment, while the LVEF increased, and the differences were statistically significant (P<0.05); Compared with the control group, the Pro-BNP, LVEDD and E/A in the study group were lower after the treatment, while the LVEF was higher, and the differences were statistically significant (P<0.05). Compared with before treatment, the serum levels of Hcy and CRP in the two groups increased after the treatment, and the differences were statistically significant (P<0.05); Compared with the control group, the serum levels of Hcy and CRP in the study group were higher after the treatment, and the differences were statistically significant (P<0.05). The clinical total effective rate of the study group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). Conclusion: Shexiangbaoxin capsules combined with salvia miltiorrhiza polyphenols in the treatment of coronary heart disease angina pectoris has significant clinical efficacy, which can improve the heart function and promote coronary flow, and it is worthy of clinical application.